Physiomics PLC Result of AGM
November 19 2024 - 10:50AM
RNS Regulatory News
RNS Number : 8525M
Physiomics PLC
19 November 2024
19
November 2024
Physiomics plc
("Physiomics" or "the Company")
Result of
AGM
Physiomics plc (AIM: PYC),
a leading mathematical modelling and data science
company supporting the development of new therapeutics and
personalised medicine solutions, is pleased to announce that all
resolutions put to shareholders at the Company's annual general
meeting, held earlier today at the Company's offices in Oxford,
were duly passed. Voting was conducted by a show of hands and
inclusive of votes received by the Company by way of
proxy.
Details of the proxy voting results
are shown in the table below.
|
Ordinary Resolutions
|
Votes For
|
%
|
Votes
Against
|
%
|
Votes
Withheld
|
Votes Total
|
% of ISC
Voted
|
|
1. Approval of the
accounts
|
13,702,827
|
98.48%
|
210,852
|
1.52%
|
5,844
|
13,919,523
|
6.8%
|
|
2. Re-appointment of
Dr Peter Sargent as a Director of the Company
|
12,408,973
|
97.73%
|
287,661
|
2.27%
|
1,222,889
|
13,919,523
|
6.8%
|
|
3. Re-election of Dr
Shalabh Kumar as a Director of the Company
|
12,408,973
|
97.73%
|
287,661
|
2.27%
|
1,222,889
|
13,919,523
|
6.8%
|
|
4. Appointment and
renumeration of auditor
|
13,697,496
|
98.45%
|
216,183
|
1.55%
|
5,844
|
13,919,523
|
6.8%
|
|
5. Authority to
allot shares
|
13,328,063
|
95.79%
|
585,616
|
4.21%
|
5,844
|
13,919,523
|
6.8%
|
|
Special Resolution
|
|
|
|
|
|
|
|
|
6. Disapplication of shareholders'
statutory pre-emption rights
|
12,108,403
|
87.03%
|
1,805,276
|
12.97%
|
5,844
|
13,919,523
|
6.8%
|
ISC
- Issued Share Capital
Enquiries:
Physiomics
plc
Dr Peter Sargent, CEO
+44 (0)1235 841575
Hybridan LLP
(broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson
Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to
Editor
About
Physiomics
Physiomics plc combines expertise
across Modelling & Simulation, Biostatistics, Data Science and
Bioinformatics, together with deep biology expertise, to help
biotech and pharma companies streamline their drug development
journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and
optimise research design across discovery, pre-clinical and
clinical studies. Through use of cutting-edge computational tools,
bespoke models and our proprietary Virtual Tumour technology, the
Physiomics team has informed the development of over 100 commercial
projects, with over 125 targets and drugs modelled. Clients include
Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
RAGGPGBCGUPCGQB
Physiomics (LSE:PYC)
Historical Stock Chart
From Nov 2024 to Dec 2024
Physiomics (LSE:PYC)
Historical Stock Chart
From Dec 2023 to Dec 2024
